Publications by authors named "Aikaterini Trevlopoulou"
Article Synopsis
- The study explores the potential of sodium nitroprusside (SNP) as a treatment for anxiety in schizophrenia, highlighting its inconsistent effects in animal models.
- It was found that a single low dose of SNP can reduce anxiety-like behavior in rats, while higher doses may depress activity levels without altering anxiety response.
- Repeated doses of SNP did not impact anxiety or activity in rats, indicating that its effects are sensitive to the dosing, timing, and treatment schedule.
Rationale: Experimental evidence indicates that the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine impairs cognition and can mimic certain aspects of positive and negative symptoms of schizophrenia in rodents. Nitric oxide (NO) is considered as an intracellular messenger in the brain, and its abnormalities have been linked to schizophrenia.
Objectives: The present study was designed to investigate the ability of the NO donor sodium nitroprusside (SNP) to counteract schizophrenia-like behavioural deficits produced by ketamine in rats.